TrialFrontiers in immunology2022

Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.

Wenying Qiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.